Diatide gets payment for AcuTect

Only days after the Food and Drug Administration cleared Diatide's acute venous thrombosis imaging agent AcuTect (SCAN 9/30/98), the Londonderry, NH, radiopharmaceutical firm received a $2 million milestone payment from marketing partner Nycomed Amersham of Buckinghamshire, U.K. The cash is the second payment Diatide has received from Nycomed Amersham in the last two months: In August, Diatide received $2 million for filing a new drug application for NeoTect, its lung cancer imaging agent.